Castellan Group’s TG Therapeutics TGTX Stock Holding History

Castellan Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-283,679	Closed	-$8.54M	–	77
2024 Q4	$8.54M	Buy	+283,679	New	+$8.14M	3.7%	3

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Castellan Group's TGTX Position: Q1 2025 in Review

Castellan Group sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 283,679 shares — an estimated $8.54M sold.

Castellan Group first reported a position in TGTX in Q4 2024 and held it in 1 quarter. The position peaked at $8.54M in Q4 2024. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

Castellan Group reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
Castellan Group sold 283,679 TG Therapeutics shares in Q1 2025, an estimated $8.54M.
Castellan Group first reported a position in TG Therapeutics in Q4 2024 and held it in 1 quarter.
Castellan Group's TG Therapeutics position peaked at $8.54M in Q4 2024.
376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on Castellan Group's 13F filing for Q1 2025, filed 8 May 2025.